Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Receivables: 2021-2024

Historic Change in Receivables for IDEAYA Biosciences (IDYA) over the last 4 years, with Dec 2024 value amounting to -$17,000.

  • IDEAYA Biosciences' Change in Receivables rose 99.75% to -$17,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$15,000, marking a year-over-year increase of 92.23%. This contributed to the annual value of -$15,000 for FY2024, which is 92.23% up from last year.
  • According to the latest figures from Q4 2024, IDEAYA Biosciences' Change in Receivables is -$17,000, which was down 189.47% from $19,000 recorded in Q3 2024.
  • In the past 5 years, IDEAYA Biosciences' Change in Receivables ranged from a high of $6.5 million in Q3 2023 and a low of -$6.7 million during Q4 2023.
  • Moreover, its 3-year median value for Change in Receivables was -$15,500 (2024), whereas its average is -$91,667.
  • Data for IDEAYA Biosciences' Change in Receivables shows a peak YoY increase of 1,129.64% (in 2022) and a maximum YoY decrease of 3,909.41% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows IDEAYA Biosciences' Change in Receivables stood at $85,000 in 2021, then tumbled by 3,909.41% to -$3.2 million in 2022, then slumped by 106.45% to -$6.7 million in 2023, then soared by 99.75% to -$17,000 in 2024.
  • Its Change in Receivables stands at -$17,000 for Q4 2024, versus $19,000 for Q3 2024 and -$14,000 for Q2 2024.